Stephen Salloway on Aducanumab Still Needs to Prove Itself, Researchers Say
COMMENT Early termination of studies 301 and 302 and a dose increase midway through the trial led to an incomplete dataset and clearly complicate the interpretation of the results. However, the totality of the data provides evidence of dose-related lowering of ...